---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268154"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:48:42.069747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates

## Summary
- Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.
- Raised $327.8M in upsized IPO at $15.00 per share in September 2025.
- Plans to initiate Phase 3 schizophrenia trial with ~460 patients in Q1 2026, topline expected H2 2027.
- Appointed William Kane and Rekha Hemrajani to Board, James Rawls as SVP of Regulatory Affairs.
- Cash position of $314.5M expected to fund operations into Q2 2028.

## SEC filing metadata
- accession: 0001193125-25-268154
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/0001193125-25-268154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/d84790d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268154
- JSON: https://secwatch.observer/filing/0001193125-25-268154.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.